HC Wainwright Issues Positive Forecast for Enlivex Therapeutics (NASDAQ:ENLV) Stock Price

Enlivex Therapeutics (NASDAQ:ENLV) had its price objective boosted by HC Wainwright from $6.00 to $7.00 in a research note published on Monday,Benzinga reports. They currently have a buy rating on the stock.

Separately, D. Boral Capital reissued a “buy” rating and issued a $13.00 price objective on shares of Enlivex Therapeutics in a research report on Monday, March 3rd.

Enlivex Therapeutics Price Performance

ENLV stock opened at $1.02 on Monday. The stock has a market capitalization of $21.83 million, a P/E ratio of -1.04 and a beta of 1.11. Enlivex Therapeutics has a fifty-two week low of $0.81 and a fifty-two week high of $4.59. The business has a 50-day moving average of $1.10 and a 200-day moving average of $1.24.

Institutional Trading of Enlivex Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Millennium Management LLC bought a new position in shares of Enlivex Therapeutics in the 4th quarter valued at about $742,000. Renaissance Technologies LLC raised its stake in Enlivex Therapeutics by 112.6% in the fourth quarter. Renaissance Technologies LLC now owns 158,992 shares of the company’s stock valued at $186,000 after buying an additional 84,203 shares during the period. Finally, Two Sigma Securities LLC acquired a new stake in shares of Enlivex Therapeutics in the fourth quarter valued at approximately $26,000. 1.02% of the stock is owned by institutional investors.

About Enlivex Therapeutics

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial.